ClinicalTrials.gg
DrugBiological

Antihemophilic factor, human recombinant clinical trials

Also written ADVATE.

studies test it
23
open now
2
in phase 3
9
first study started
2001

How each study uses antihemophilic factor, human recombinant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the antihemophilic factor, human recombinant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 Dec 1992 · Bioclate (Armour), Recombinate · BLA 103375 (FDA, Purple Book)
European Union
4 Aug 2000 · Kogenate Bayer · EMEA/H/C/000275 (EMA; now lapsed)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Brand

ADVATE
9

Other names

Antihemophilic Factor (Recombinant)
1
Octocog alfa
1

In one entry with another drug

Given together, or one or the other

Antihemophilic factor, recombinant, manufactured protein-free
5
FVIII
3

Studies by the year they started

23 studies that test it; most in 2009 (4)

Studies that test antihemophilic factor, human recombinant, by start year
YearStudies
20012
20021
20062
20081
20094
20101
20112
20143
20152
20171
20201
20221
20252

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
3
Phase 3
9
Phase 4
8
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 9

Baxalta now part of Shire (9) · Bayer (3) · Children's Hospital Los Angeles (1) · Oregon Health and Science University (1) · Fondazione Angelo Bianchi Bonomi (1) · Novo Nordisk A/S (1) · Chulalongkorn University (1) · Takeda (1)

Often tested with

Tested in the same studies.

F8 protein, human (9) · Factor VIII (3) · Vonicog alfa (2) · Factor VIII, von Willebrand factor drug combination (1) · Optivate (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Antihemophilic factor, human recombinant is the comparator. A study of two new drugs counts under both.

  • 1Emicizumab · Hoffmann-La Roche · next primary completion Oct 2027
Reaching primary completion within a year · 1, 1 in phase 3

Studies that test antihemophilic factor, human recombinant, phase 3 first.

Studies

Open first, then newest update. How each study uses antihemophilic factor, human recombinant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test antihemophilic factor, human recombinant →

Given beside what is tested · 11 — antihemophilic factor, human recombinant is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with antihemophilic factor, human recombinant

Codes

What other systems call antihemophilic factor, human recombinant · ClinicalTrials.gg INT017558

  • UNII (FDA) P89DR4NY54ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANTConfirmed FDA, Wikidata
  • RxNorm 1300486Confirmed FDA, Wikidata
  • Wikidata Q4661156antihemophilic factor, human recombinantConfirmed FDA, Wikidata
  • NCI Thesaurus C81123Antihemophilic Factor, Human RecombinantConfirmed FDA, Wikidata
  • DrugBank DB00025One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.